This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Elevance Health (ELV) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights Accenture, Elevance Health, Analog Devices, Monster Beverage and West Pharmaceutical Services
by Zacks Equity Research
Accenture, Elevance Health, Analog Devices, Monster Beverage and West Pharmaceutical Services are part of the Zacks top Analyst Blog.
Top Research Reports for Accenture, Elevance Health & Analog Devices
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Elevance Health, Inc. (ELV) and Analog Devices, Inc. (ADI).
Alcon (ALC) Q2 Earnings Surpass Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) delivers better-than-expected earnings and revenues in the second quarter of 2023.
Here's Why Elevance Health (ELV) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Asensus Surgical (ASXC) Q2 Loss Widens, Revenues In Line
by Zacks Equity Research
Asensus Surgical (ASXC) reports a significant increase in total surgical procedures completed utilizing the Senhance System.
National Vision (EYE) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
National Vision's (EYE) second-quarter 2023 performance highlights positive comparable store sales growth, retention and recruitment trends.
Here's How Much You'd Have If You Invested $1000 in Elevance Health a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Charles River (CRL) Q2 Earnings Top, 2023 View Narrowed
by Zacks Equity Research
Charles River (CRL) registers robust growth in small research models, research model services and the Safety Assessment business.
Insulet (PODD) Q2 Earnings Beat, Sales Growth View Raised
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 gains market share in the second quarter within the diabetes technology market as the only FDA-approved fully disposable, pod-based automated insulin delivery system.
QIAGEN (QGEN) Q2 Earnings and Revenues Top, '23 View Slashed
by Zacks Equity Research
QIAGEN (QGEN) surpasses the earnings and revenue outlook in the second quarter of 2023 amid a challenging macro environment.
SmileDirectClub (SDC) Q2 Earnings Miss Estimates, '23 View Up
by Zacks Equity Research
SmileDirectClub (SDC) reports a higher-than-expected loss in the second quarter of 2023.
Henry Schein (HSIC) Q2 Earnings Top, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) second quarter 2023 performance demonstrates strength in the North American dental business.
Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.
ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.
Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View
by Zacks Equity Research
Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.
Stryker (SYK) Q2 Earnings Beat Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Cigna (CI) Q2 Earnings Beat on Strong U.S. Commercial Unit
by Zacks Equity Research
Cigna's (CI) Q2 results reflect solid premium rate hikes and a growing membership base across its U.S. Commercial and Medicare Advantage businesses.
Envista (NVST) Q2 Earnings Top Estimates, Margins Expands
by Zacks Equity Research
Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.
Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
STERIS (STE) Q1 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Barring Life Sciences and Dental, rest of STERIS (STE) operating segments report organic revenue growth in fiscal Q1.
McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.
Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.
DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.